Scott Rudge
About Scott Rudge
Scott Rudge is an Adjunct Professor of Chemical Engineering with extensive experience in project management within the pharmaceutical and biotechnology sectors. He has held significant roles, including COO at RMC Pharmaceutical Solutions and founder of Syner-G BioPharma Group, while also focusing on developing people and problem-solving skills in his professional endeavors.
Work at University of Colorado
Scott Rudge has served as an Adjunct Professor of Chemical Engineering at the University of Colorado since 1998. In this role, he imparts knowledge and expertise in chemical engineering, focusing on project management in the pharmaceutical and biotechnology sectors. His long tenure at the university reflects his commitment to education and the development of future professionals in the field.
Education and Expertise
Scott Rudge holds a Bachelor of Science in Chemical Engineering from Worcester Polytechnic Institute, which he completed from 1980 to 1984. He furthered his education by obtaining a Ph.D. in Chemical Engineering from Purdue University, studying from 1984 to 1989. His academic background provides a strong foundation for his specialization in project management, process development engineering, and problem-solving in the pharmaceutical and biotechnology industries.
Background in Pharmaceutical Industry
Scott Rudge has extensive experience in the pharmaceutical and biotechnology industries. He served as the Chief Operating Officer at RMC Pharmaceutical Solutions for 20 years, from 2003 to 2023. His responsibilities included overseeing operations and ensuring compliance in chemistry, manufacturing, and controls. Additionally, he worked as a Staff Scientist at NIST from 1989 to 1991, contributing to research and development in the field.
Current Role at Syner-G BioPharma Group
In 2023, Scott Rudge founded Syner-G BioPharma Group, where he currently serves as Founder. The company is based in Boulder, Colorado, and operates in a hybrid model. His focus at Syner-G includes developing broad-spectrum antibiotics, showcasing his commitment to addressing critical health challenges through innovative solutions.